Merck stock

MRK · NYSE · USD

$147.76Change from previous close: +0.55%Absolute change: +$0.81

Close · November 13, 2026

Price history

+59.00% over the period

1 year: from $92.93 (November 13, 2025) to $147.76 (November 13, 2026), +59.00%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$147.76
October 30, 2026$149.52
September 30, 2026$145.31
August 31, 2026$147.76
July 31, 2026$130.20
June 30, 2026$128.50
May 29, 2026$118.72
April 30, 2026$109.18
March 31, 2026$120.29
February 27, 2026$123.82
January 30, 2026$110.27
December 31, 2025$105.26
November 28, 2025$104.83
November 13, 2025$92.93

At a glance

  • The company

    Develops and markets pharmaceuticals for human health, vaccines, and veterinary medicines and health solutions

  • Latest results

    Quarter to September 30, 2026 · EPS $2.49 (estimate $2.09)

TickerLandia's take on Merck

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$92.11
52-wk high$156.92

−5.84% from the 52-week high

Analysts · 28 analysts

Average target$161.53+9.32% vs. price

Buy 19 · Hold 9 · Sell 0 · Buy

TickerLandia Fingerprint: Merck

Compared with similar companies: very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Merck is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Merck's P/E today is 20.3, in line with the median of its last 9 fiscal years (22.8; between 14.5 and 61.7 from 2016 to 2025). Merck's P/E (trailing 12 months): 147.8, +249% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Merck's metrics compared with similar companies
MetricMerckPosition in the groupBand
P/E (trailing 12 months)147.8High
Forward P/E16.5Middle
Operating margin35.2%Middle
ROE5.1%Middle
Debt/equity1.20Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Merck. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$18.09B

Latest quarter · Q3 2026

Net income

$5.07B

Latest quarter · Q3 2026

Quarterly net margin

28.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$364.26B
P/E
147.8
EPS
$1.00
Volume
6.5M
Daily trading
€1.28B
Dividend yield
2.30%
Last ex-dividend on September 15, 2026

How Merck is changing

All results
  • Revenue grew 9.4% a year on average over the last 5 years

  • Operating margin rose from 34.6% to 37.6%

  • Profits turn into cash: free cash flow equal to 111% of net income

Returns

Merck returns with dividends

$1,000 invested in Merck 5 years ago, on November 15, 2021, would be worth $2,057 today with dividends reinvested: +105.66% in total, +15.53% per year. On price alone it would be $1,766 (+76.56%).

PeriodMerckS&P 500$1,000 becomes
1 month+4.07%−3.12%$1,041
6 months+30.24%+1.58%$1,302
Year to date+40.38%+10.46%$1,404
1 year+63.69%+12.23%$1,637
3 years+58.04%+71.41%$1,580
5 years+105.66%+61.48%$2,057
10 years+230.73%+249.40%$3,307

Over the last 6 months it has done better than 68% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Merck: technical analysis

Merck is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.6% below its highest close since January 2, 1990 ($156.45, August 25, 2026).

Trend
Upward
RSI (14 sessions)
53
Between 30 and 70
vs 200-session average
+14.86%

Support and resistance

Price areas where Merck has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$153.44+3.84%4 touches, last on November 5, 2026
  2. Last price$147.76
  3. Support$142.56−3.52%2 touches, last on November 6, 2026
  4. Support$139.01−5.93%2 touches, last on October 28, 2026
  5. Support$131.01−11.33%2 touches, last on July 17, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.22
Volatility (60 sessions, annualised)
28.1%
Largest fall in the last year
−11.90%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Merck: seasonality

Average monthly price change over 37 years

+1.0%Jan−0.7%Feb−0.7%Mar+1.3%Apr+1.6%May+1.2%Jun−0.4%Jul+0.4%Aug−0.8%Sep+2.4%Oct+3.4%Nov+1.3%Dec

Over the last 37 years, the strongest month for Merck has been November: +3.40% on average, positive in 25 years out of 36. The weakest has been September: −0.77% on average, positive in 17 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+0.99%+2.22%21 of 36
February−0.73%−1.20%15 of 37
March−0.74%+0.49%22 of 37
April+1.30%+2.13%22 of 37
May+1.64%+1.87%23 of 37
June+1.25%+0.42%19 of 37
July−0.37%−0.42%16 of 37
August+0.39%−0.03%18 of 37
September−0.77%−0.61%17 of 37
October+2.37%+2.44%21 of 37
November+3.40%+4.19%25 of 36
December+1.28%+0.83%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Merck and its competitors

Customers for Merck & Co., Inc.'s human health medicines, vaccines and animal health products are spread across markets worldwide, with the United States and EMEA accounting for most of its revenue. The company sells prescription medicines and vaccines for human patients, including Keytruda, Gardasil, Januvia and Winrevair, and veterinary pharmaceuticals for livestock and companion animals, under brands such as Bravecto, Nobivac NXT and Bovilis. It also offers Allflex Livestock Intelligence solutions and has collaboration agreements with Daiichi Sankyo, AstraZeneca, Moderna and LaNova.

Headquarters
Rahway, United States
Employees
73,000
Founded
2000
Chief executive
Robert Davis
Merck and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
MerckMRK$364.26B35.2%147.8+30.24%
AbbVieABBV$521.5B36.6%50.6+41.50%
AmgenAMGN$251.89B34.1%27.0+38.41%
Gilead SciencesGILD$208.48B38.2%—+26.33%
Johnson & JohnsonJNJ$687.89B26.6%43.4+24.01%
PfizerPFE$164.67B29.1%41.3+11.29%

Same industry or related industries, similar size. Compare Merck with its competitors · Full profile